William Blair research analyst Matt Phipps was quoted in this CNBC outlook story covering how healthcare stocks will perform in 2023.
“Several companies that had provided strong clinical data were able to raise funds [in 2022],” Phipps said.
Equity Research
William Blair research analyst Matt Phipps was quoted in this CNBC outlook story covering how healthcare stocks will perform in 2023.
“Several companies that had provided strong clinical data were able to raise funds [in 2022],” Phipps said.
Stay up-to-date with the latest William Blair news
William Blair initiated research coverage of MDxHealth SA (MDXH $2.86), a commercial-stage diagnostics company providing actionable molecular diagnostic information to personalize diagnosis and treatment of prostrate cancer and other urologic diseases.
Read moreIn this Economics Weekly, we thought it worth having a look at the current situation in commercial real estate.
Read moreWilliam Blair initiated research coverage of Intuitive Surgical, Inc. (ISRG $246.68), which offers an ecosystem of minimally invasive surgical products and services that are founded on its da Vinci robotic system.
Read moreInformation contained on the internet is not subject to William Blair & Company's control or review, and may not be accurate.
For disclosure information, please visit www.williamblair.com/disclosures